Chemicals · Founded 1989 · www.neogenchem.com · BSE 542665 · NSE NEOGEN · ISIN INE136S01016
No Notes Added Yet
Business
Neogen Chemicals Ltd. is an Indian specialty chemicals manufacturer focusing on bromine-based and lithium-based advanced intermediates. The company develops and manufactures specialty organic chemicals, inorganic chemicals, and pharmaceutical intermediates. Its products serve diverse end-user industries including pharmaceuticals, agrochemicals, engineering, electronic chemicals, battery chemicals, and construction chemicals. Neogen operates on a business-to-business (B2B) model, providing customized and complex chemical solutions to its clients, thereby making money through the sale of these specialty chemical products.
Revenue Mix
Neogen's business is primarily divided into:
Bromine-based Specialty Chemicals: This segment includes a wide range of organic and inorganic bromine compounds used in pharmaceuticals, agrochemicals, flame retardants, and other industrial applications.
Lithium-based Specialty Chemicals: This segment focuses on lithium salts and derivatives, which are crucial components, particularly for the rapidly growing lithium-ion battery market (Electric Vehicles, energy storage) and also in pharmaceutical synthesis.
While specific real-time revenue contributions vary, both segments are strategic, with lithium-based chemicals expected to be a significant growth driver due to their application in new-age technologies.
Industry
Neogen operates within the Indian specialty chemicals industry, a sector characterized by high entry barriers due to complex manufacturing processes, specific client approvals, and R&D intensity. The industry benefits from global supply chain diversification away from China (China+1 strategy) and strong domestic demand. Neogen is positioned as a niche player specializing in complex bromine and lithium chemistries, which gives it an edge over generic chemical manufacturers. Its focus on import substitution and catering to critical industries like pharmaceuticals and EV batteries places it in a high-growth sub-segment.
MOAT
Neogen's competitive advantages include:
Niche Expertise & R&D: Deep expertise in bromine and lithium chemistry allows it to develop and manufacture complex, high-value-added products that require specialized knowledge and processes. This creates barriers for new entrants.
Long-standing Customer Relationships & Approvals: Building trust and securing approvals from global pharmaceutical and industrial clients takes years, leading to sticky customer relationships and preferred supplier status.
Custom Synthesis Capabilities: Ability to offer custom synthesis and contract manufacturing services for specific client requirements, which fosters client dependence and repeat business.
Process Know-how: Proprietary manufacturing processes and safety protocols for handling hazardous chemicals like bromine.
Growth Drivers
Key factors that can drive Neogen's growth include:
Electric Vehicle (EV) Adoption: Rapid global and domestic adoption of EVs will significantly boost demand for lithium-ion batteries and, consequently, Neogen's lithium-based chemicals.
"China+1" Strategy: Global supply chain de-risking benefits Indian specialty chemical manufacturers as global companies seek alternative sourcing options.
Capacity Expansion: Ongoing capital expenditure plans to expand manufacturing capacities for both existing and new product lines, particularly in lithium-ion battery chemicals.
New Product Development & Import Substitution: Continuous R&D efforts to develop new, advanced specialty chemicals and substitute imported products, expanding market reach and reducing reliance on imports.
Growth in End-User Industries: Sustained growth in pharmaceuticals, agrochemicals, and other industrial sectors globally and domestically.
Risks
Raw Material Price Volatility: Dependence on imported and domestically sourced raw materials like bromine and various lithium salts, whose prices are subject to global supply-demand dynamics and currency fluctuations.
Intense Competition: Competition from established domestic and international specialty chemical players, particularly from China.
Technological Obsolescence: Rapid advancements in battery technology or chemical synthesis processes could potentially render some current product lines less competitive.
Environmental & Regulatory Risks: Strict environmental regulations and the hazardous nature of chemicals handled require continuous compliance and investment in safety measures.
Customer Concentration: While not explicitly high, dependence on a few large clients in niche segments could pose a risk if business from them declines.
Project Execution Risk: Delays or cost overruns in ongoing capacity expansion projects could impact financial performance.
Management & Ownership
Neogen Chemicals is promoted by the Haria family, with Mr. Harin Kanani as the Managing Director. The promoters have a deep understanding of the chemical industry, having been involved in the business for several decades. The management team generally comprises experienced professionals in chemistry, operations, and finance. The promoter group holds a significant stake in the company, aligning their interests with those of public shareholders. Institutional investors also hold a notable portion, indicating confidence in the company's prospects.
Outlook
Neogen Chemicals is well-positioned in the growing Indian specialty chemicals sector, particularly benefiting from the structural tailwinds of global supply chain diversification and the burgeoning demand for lithium-ion battery chemicals. The company's niche expertise in complex chemistries and focus on R&D provides a solid foundation for growth. The increasing adoption of EVs and energy storage solutions presents a significant long-term opportunity for its lithium-based products. However, the company faces risks from raw material price volatility, intense competition, and the execution of its ambitious capacity expansion plans. While the long-term growth trajectory appears favorable due to its strategic focus and strong market positioning, successful execution of projects and efficient management of raw material costs will be crucial for sustained profitability.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 200 | 180 | 193 | 201 | 203 | 187 | 209 | 220 | 247 | 250 |
| Other Income | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 4 |
| Total Income | 202 | 182 | 194 | 202 | 203 | 188 | 211 | 222 | 248 | 254 |
| Total Expenditure | 164 | 149 | 159 | 167 | 166 | 155 | 179 | 188 | 203 | 202 |
| Operating Profit | 38 | 32 | 35 | 36 | 37 | 33 | 32 | 34 | 45 | 52 |
| Interest | 10 | 10 | 13 | 13 | 13 | 13 | 19 | 22 | 21 | 21 |
| Depreciation | 6 | 7 | 7 | 7 | 7 | 6 | 7 | 7 | 8 | 8 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -14 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 22 | 16 | 15 | 15 | 4 | 14 | 5 | 6 | 16 | 23 |
| Provision for Tax | 6 | 4 | 5 | 5 | 1 | 4 | 2 | 2 | 4 | 6 |
| Profit After Tax | 17 | 11 | 11 | 10 | 2 | 10 | 3 | 4 | 11 | 17 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 17 | 11 | 11 | 10 | 2 | 10 | 3 | 4 | 11 | 17 |
| Adjusted Earnings Per Share | 6.4 | 4.3 | 4.2 | 3.8 | 0.9 | 3.9 | 1.3 | 1.4 | 4.3 | 6.2 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 100 | 110 | 161 | 239 | 306 | 336 | 487 | 686 | 691 | 778 | 862 | 926 |
| Other Income | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 4 | 7 | 4 | 6 | 9 |
| Total Income | 100 | 110 | 162 | 240 | 306 | 337 | 488 | 691 | 698 | 782 | 868 | 935 |
| Total Expenditure | 86 | 90 | 132 | 196 | 248 | 272 | 401 | 575 | 581 | 641 | 725 | 772 |
| Operating Profit | 14 | 20 | 30 | 44 | 58 | 65 | 88 | 116 | 118 | 140 | 143 | 163 |
| Interest | 5 | 8 | 10 | 12 | 12 | 14 | 19 | 29 | 42 | 49 | 75 | 83 |
| Depreciation | 1 | 1 | 2 | 3 | 5 | 7 | 12 | 16 | 23 | 28 | 28 | 30 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -14 | 0 | 0 |
| Profit Before Tax | 8 | 11 | 17 | 29 | 41 | 44 | 57 | 71 | 53 | 50 | 41 | 50 |
| Provision for Tax | 3 | 4 | 6 | 8 | 12 | 13 | 12 | 21 | 17 | 15 | 12 | 14 |
| Profit After Tax | 5 | 8 | 11 | 21 | 29 | 31 | 45 | 50 | 36 | 35 | 29 | 35 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 5 | 8 | 11 | 21 | 29 | 31 | 45 | 50 | 36 | 35 | 29 | 35 |
| Adjusted Earnings Per Share | 2.6 | 3.8 | 5.5 | 10.4 | 12.3 | 13.4 | 17.9 | 20 | 13.5 | 13.2 | 10.9 | 13.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 11% | 8% | 21% | 24% |
| Operating Profit CAGR | 2% | 7% | 17% | 26% |
| PAT CAGR | -17% | -17% | -1% | 19% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 59% | 11% | 14% | NA% |
| ROE Average | 4% | 5% | 8% | 17% |
| ROCE Average | 7% | 8% | 10% | 17% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 28 | 42 | 50 | 70 | 156 | 183 | 439 | 483 | 760 | 789 | 816 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 5 | 37 | 38 | 51 | 30 | 116 | 122 | 129 | 124 | 170 | 819 |
| Other Non-Current Liabilities | 3 | 7 | 8 | 9 | 18 | 15 | 20 | 32 | 50 | 54 | 79 |
| Total Current Liabilities | 46 | 67 | 84 | 117 | 150 | 178 | 218 | 410 | 527 | 733 | 1188 |
| Total Liabilities | 80 | 152 | 180 | 246 | 355 | 492 | 799 | 1054 | 1461 | 1747 | 2902 |
| Fixed Assets | 17 | 56 | 67 | 83 | 111 | 127 | 285 | 347 | 496 | 404 | 475 |
| Other Non-Current Assets | 2 | 6 | 7 | 4 | 13 | 125 | 22 | 51 | 182 | 344 | 1035 |
| Total Current Assets | 61 | 90 | 107 | 160 | 231 | 240 | 492 | 656 | 784 | 1000 | 1393 |
| Total Assets | 80 | 152 | 180 | 246 | 355 | 492 | 799 | 1054 | 1461 | 1747 | 2902 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 2 | 2 | 3 | 2 | 2 | 1 | 1 | 45 | 21 | 13 | 5 |
| Cash Flow from Operating Activities | 9 | 0 | 12 | -4 | -35 | 84 | 1 | -30 | -29 | 196 | -231 |
| Cash Flow from Investing Activities | -4 | -33 | -13 | -20 | -29 | -135 | -146 | -94 | -216 | -317 | -410 |
| Cash Flow from Financing Activities | -4 | 33 | -0 | 24 | 63 | 51 | 188 | 100 | 237 | 113 | 642 |
| Net Cash Inflow / Outflow | 0 | 1 | -1 | 0 | -1 | -0 | 44 | -25 | -8 | -8 | -0 |
| Closing Cash & Cash Equivalent | 2 | 3 | 2 | 2 | 1 | 1 | 45 | 21 | 13 | 5 | 5 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 2.59 | 3.84 | 5.49 | 10.43 | 12.28 | 13.43 | 17.89 | 20.04 | 13.51 | 13.2 | 10.9 |
| CEPS(Rs) | 3.09 | 4.48 | 6.42 | 11.85 | 14.53 | 16.39 | 22.58 | 26.53 | 22.18 | 23.74 | 21.33 |
| DPS(Rs) | 0.45 | 0 | 1 | 1.5 | 2 | 2.25 | 2.75 | 3 | 2 | 1 | 1 |
| Book NAV/Share(Rs) | 13.77 | 20.98 | 25.21 | 34.96 | 66.96 | 78.44 | 176.12 | 193.47 | 288.21 | 299.24 | 309.43 |
| Core EBITDA Margin(%) | 12.96 | 16.45 | 17.68 | 16.99 | 16.7 | 16.06 | 17.77 | 16.27 | 15.83 | 17.44 | 15.89 |
| EBIT Margin(%) | 12.19 | 15.63 | 16.98 | 16.12 | 15.25 | 14.47 | 15.63 | 14.57 | 13.64 | 12.62 | 13.45 |
| Pre Tax Margin(%) | 7.79 | 9.44 | 10.62 | 11.45 | 11.82 | 11.03 | 11.71 | 10.35 | 7.59 | 6.42 | 4.75 |
| PAT Margin (%) | 4.76 | 6.29 | 6.7 | 8.2 | 8.24 | 7.82 | 9.16 | 7.28 | 5.13 | 4.46 | 3.33 |
| Cash Profit Margin (%) | 5.68 | 7.37 | 7.83 | 9.31 | 9.75 | 9.54 | 11.56 | 9.64 | 8.42 | 8.01 | 6.51 |
| ROA(%) | 6.94 | 6.57 | 6.6 | 9.81 | 9.53 | 7.4 | 6.91 | 5.39 | 2.83 | 2.17 | 1.24 |
| ROE(%) | 20.3 | 22 | 23.78 | 34.73 | 25.31 | 18.47 | 14.34 | 10.84 | 5.74 | 4.5 | 3.58 |
| ROCE(%) | 26.11 | 23.01 | 22.85 | 25.52 | 21.93 | 16.75 | 14.33 | 13.25 | 9.49 | 7.86 | 6.64 |
| Receivable days | 56.68 | 72.13 | 81.81 | 72.86 | 71.35 | 70.02 | 70.43 | 76.3 | 120.51 | 112.52 | 122.62 |
| Inventory Days | 93.95 | 107.83 | 100.15 | 87.39 | 106.19 | 111.05 | 115.59 | 129.67 | 177.31 | 161.47 | 185.31 |
| Payable days | 114.11 | 150.54 | 130.19 | 103.11 | 77.99 | 94.13 | 109.49 | 119.98 | 143.69 | 175.91 | 275.96 |
| PER(x) | 0 | 0 | 0 | 0 | 28.59 | 64.36 | 97.51 | 64.03 | 88.26 | 117.02 | 102.04 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 5.24 | 11.02 | 9.91 | 6.63 | 4.14 | 5.16 | 3.59 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0.57 | 0.26 | 0.16 | 0.23 | 0.17 | 0.06 | 0.09 |
| EV/Net Sales(x) | 0.44 | 0.78 | 0.62 | 0.58 | 3.12 | 6.63 | 9.3 | 5.16 | 5.11 | 5.96 | 4.94 |
| EV/Core EBITDA(x) | 3.08 | 4.24 | 3.39 | 3.14 | 16.42 | 34.59 | 51.69 | 30.51 | 30.02 | 33.04 | 29.69 |
| Net Sales Growth(%) | 19.52 | 9.74 | 46.41 | 48.34 | 28.05 | 9.89 | 44.84 | 40.83 | 0.65 | 12.58 | 10.85 |
| EBIT Growth(%) | 4.35 | 43.04 | 46.66 | 47.95 | 28.72 | 9.35 | 31.34 | 31.28 | -5.14 | 4.04 | 17.77 |
| PAT Growth(%) | 1.87 | 47.59 | 43.68 | 90.7 | 36.81 | 9.33 | 42.45 | 11.97 | -28.66 | -2.3 | -17.46 |
| EPS Growth(%) | 1.77 | 48.32 | 42.97 | 89.94 | 17.72 | 9.35 | 33.25 | 11.97 | -32.55 | -2.3 | -17.46 |
| Debt/Equity(x) | 0.96 | 1.65 | 1.63 | 1.71 | 0.88 | 1.18 | 0.51 | 0.75 | 0.52 | 0.72 | 1.63 |
| Current Ratio(x) | 1.34 | 1.35 | 1.28 | 1.37 | 1.54 | 1.35 | 2.26 | 1.6 | 1.49 | 1.36 | 1.17 |
| Quick Ratio(x) | 0.64 | 0.75 | 0.68 | 0.75 | 0.68 | 0.71 | 1.36 | 0.89 | 0.76 | 0.94 | 0.69 |
| Interest Cover(x) | 2.77 | 2.53 | 2.67 | 3.45 | 4.45 | 4.21 | 3.99 | 3.45 | 2.25 | 2.03 | 1.55 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0.17 | 0.11 | 0.05 | 0.11 | 0.13 | 0.14 | 0.45 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 56.89 | 56.89 | 51.23 | 51.23 | 51.23 | 51.23 | 51.23 | 51.23 | 51.23 | 53.01 |
| FII | 4.56 | 4.65 | 8.17 | 7.73 | 7.79 | 7.36 | 5.15 | 4.57 | 4.46 | 4.11 |
| DII | 22.14 | 22.54 | 22.48 | 22.53 | 22.75 | 22.96 | 25.23 | 21.99 | 22.64 | 19.6 |
| Public | 16.41 | 15.92 | 18.12 | 18.51 | 18.23 | 18.45 | 18.39 | 22.21 | 21.67 | 23.28 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.5 | 1.5 | 1.35 | 1.35 | 1.35 | 1.35 | 1.35 | 1.35 | 1.35 | 1.45 |
| FII | 0.12 | 0.12 | 0.22 | 0.2 | 0.21 | 0.19 | 0.14 | 0.12 | 0.12 | 0.11 |
| DII | 0.58 | 0.59 | 0.59 | 0.59 | 0.6 | 0.61 | 0.67 | 0.58 | 0.6 | 0.54 |
| Public | 0.43 | 0.42 | 0.48 | 0.49 | 0.48 | 0.49 | 0.49 | 0.59 | 0.57 | 0.64 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.64 | 2.64 | 2.64 | 2.64 | 2.64 | 2.64 | 2.64 | 2.64 | 2.64 | 2.74 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +11% | +8% | +21% | +24% |
| Operating Profit CAGR | +2% | +7% | +17% | +26% |
| PAT CAGR | -17% | -17% | -1% | +19% |
| Share Price CAGR | +59% | +11% | +14% | — |
| ROE Average | +4% | +5% | +8% | +17% |
| ROCE Average | +7% | +8% | +10% | +17% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 56.89 | 56.89 | 51.23 | 51.23 | 51.23 | 51.23 | 51.23 | 51.23 | 51.23 | 53.01 |
| FII | 4.56 | 4.65 | 8.17 | 7.73 | 7.79 | 7.36 | 5.15 | 4.57 | 4.46 | 4.11 |
| DII | 22.14 | 22.54 | 22.48 | 22.53 | 22.75 | 22.96 | 25.23 | 21.99 | 22.64 | 19.6 |
| Public | 16.41 | 15.92 | 18.12 | 18.51 | 18.23 | 18.45 | 18.39 | 22.21 | 21.67 | 23.28 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.5 | 1.5 | 1.35 | 1.35 | 1.35 | 1.35 | 1.35 | 1.35 | 1.35 | 1.45 |
| FII | 0.12 | 0.12 | 0.22 | 0.2 | 0.21 | 0.19 | 0.14 | 0.12 | 0.12 | 0.11 |
| DII | 0.58 | 0.59 | 0.59 | 0.59 | 0.6 | 0.61 | 0.67 | 0.58 | 0.6 | 0.54 |
| Public | 0.43 | 0.42 | 0.48 | 0.49 | 0.48 | 0.49 | 0.49 | 0.59 | 0.57 | 0.64 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.64 | 2.64 | 2.64 | 2.64 | 2.64 | 2.64 | 2.64 | 2.64 | 2.64 | 2.74 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.